Optimal dosing of rivaroxaban is undefinedBMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i5549 (Published 18 October 2016) Cite this as: BMJ 2016;355:i5549
- Thomas J Moore, senior scientist
- Institute for Safe Medication Practices, 101 N Columbus St, Suite 410, Alexandria, VA 22314, USA
The faulty INRatio device used in the rivaroxaban ROCKET atrial fibrillation trial1 is particularly important in light of another drawback to this novel oral anticoagulant (NOAC). Rivaroxaban has the shortest terminal half life of the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial